🇺🇸 FDA
Patent

US 9592271

Angiopoietin-based interventions for treating cerebral malaria

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 9592271 (Angiopoietin-based interventions for treating cerebral malaria) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/357